@ARTICLE{Wieczorek-Surdacka_Ewa_Novel_2020,
 author={Wieczorek-Surdacka, Ewa and Surdacki, Andrzej and Świerszcz, Jolanta and Chyrchel, Bernadeta},
 volume={Vol. 60},
 number={No 4},
 journal={Folia Medica Cracoviensia},
 pages={97-101},
 howpublished={online},
 year={2020},
 publisher={Oddział PAN w Krakowie; Uniwersytet Jagielloński – Collegium Medicum},
 abstract={Intensive hypoglycemic treatment is the strongest preventive strategy against the development of microvascular complications of type 2 diabetes (T2DM), including diabetic nephropathy. However, some antidiabetic drugs, i.e. sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP1-RA) have an additional renoprotective effect beyond glucose control by itself. Similar, both SGLT-2i and GLP1-RA have been demonstrated to decrease the risk of adverse cardiovascular (CV) events in CV outcome trials. Nevertheless, there are relevant differences in CV and renal effects of SGLT-2i and GLP1-RA. First, SGLT2i reduced the incidence and progression of albuminuria and prevented loss of kidney function, while predominant renal benefits of GLP1-RA were driven by albuminuria outcomes. Second, the risk of heart failure (HF) hospitalizations decreased on SGLT2i but not on GLP1-RA, which gives priority to SGLT2i in T2DM and HF, especially with depressed EF. Third, either GLP1-RA (reducing predominantly atherosclerosis-dependent events) or SGLT-2i, should be used in T2DM and established atherosclerotic CV disease (ASCVD) or other indicators of high CV risk. In this review, we have briefly compared clinical practice guidelines of the American Diabetes Association (2020 and 2021 versions), Polish Diabetes Association (2020) and the European Society of Cardiology/European Association for the Study of Diabetes (2019), with a focus on the choice between SGLT-2i and GLP1-RA in patients with diabetic kidney disease.},
 type={Article},
 title={Novel antidiabetic drugs in diabetic kidney disease accompanying type 2 diabetes — a minireview},
 URL={http://journals.pan.pl/Content/119096/PDF/2020-04-FMC-08-Wieczorek.pdf},
 doi={10.24425/fmc.2020.136207},
 keywords={sodium-glucose cotransporter-2 inhibitors, glucagon-like peptide-1 receptor agonists, renoprotection, diabetic kidney disease, type 2 diabetes, cardiovascular outcome trials, clinical practice guidelines},
}